Lymphocyte therapy of renal cell carcinoma

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. Cancer J. Clin. 55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Curti BD. Renal cell carcinoma. JAMA 292, 97–100 (2004).
   PubMed Web of Science ®Google Scholar
• Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983–1993. Semin. Oncol. 22, 42–60 (1995).
   PubMed Web of Science ®Google Scholar
• Motzer RJ. Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J. Clin. Oncol. 21, 1193–1194 (2003).
   PubMed Web of Science ®Google Scholar
• Minasian LM, Motzer RJ, Gluck L et al. Interferon α-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11, 1368–1375 (1993).
   PubMed Web of Science ®Google Scholar
• Fyfe GA, Fisher RI, Rosenberg SA et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14, 2410 (1996).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Church C, Barth NM et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother. 12, 243–248 (1997).
   Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55–S57 (2000).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 10, 6388S–6392S (2004).
   PubMed Web of Science ®Google Scholar
• Sakamoto KM. Su-11248 Sugen. Curr. Opin. Investig. Drugs 5, 1329–39 (2004).
   PubMedGoogle Scholar
• Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 20, 416–418 (1997).
   PubMed Web of Science ®Google Scholar
• Naito J, Belldegrun AS. Interferon and kidney cancer: a promise unfulfilled? Cancer J. Sci. Am. 4, 155–156 (1998).
   PubMedGoogle Scholar
• Dutcher JP. Interleukin-2 based therapy for kidney cancer. Cancer Treat. Res. 116, 155–172 (2003).
   PubMedGoogle Scholar
• Dillman RO. Antibody therapy. In: Principles of Cancer Biotherapy. Fourth Edition. Oldham RK (Ed.). Kluwer Academic Publishers, The Netherlands, 329–390 (2003).
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexperessing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554–3561 (2002).
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).
   PubMed Web of Science ®Google Scholar
• Dillman RO. Radiolabeled anti-cd20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol. 20, 3545–3557 (2002).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson D, Fehrenbacher L, Novotny W et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblit Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Bleumer L, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90(5), 985–990 (2004).
   PubMed Web of Science ®Google Scholar
• Hiserodt JC. Lymphokine-activated killer cells: biology and relevance to disease. Cancer Invest. 11, 420–439 (1993).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymhokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interlelukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889–897 (1987).
   PubMed Web of Science ®Google Scholar
• West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898–905 (1987).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180–199 (1992).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Coltman Jr CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med. 108, 518–523 (1988).
   PubMed Web of Science ®Google Scholar
• Foon KA, Walther PJ, Bernstein ZP et al. Renal cell carcinoma treated with continuous-infusion interleukin-2 wioth ex vivo-activated killer cells. J. Immunother. 11, 184–190 (1992).
   PubMedGoogle Scholar
• Thompson JA, Shulma KL, Benyunes MC et al. Prolonged continuous intravenous infusion interleukin-2 and lyhmphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 10, 960–968 (1992).
   PubMed Web of Science ®Google Scholar
• Parkinson DR, Fisher RI, Rayner AA et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol. 8, 1630–1636 (1990).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R. In-patient continuous-infusion interluekin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71, 2358–2370 (1993).
   PubMedGoogle Scholar
• Sznol M, Clark JW, Smith JW et al. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon α-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl Cancer Inst. 84, 929–937 (1992).
   PubMedGoogle Scholar
• Palmer PA, Vinke J, Evers P et al. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur. J. Cancer 28A, 1038–1044 (1992).
   PubMed Web of Science ®Google Scholar
• Kruit WH, Goey SH, Lamers CHJ et al. High-dose regimen of interleukin-2 and interferon-α in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J. Immunother. 20, 312–320 (1997).
   PubMed Web of Science ®Google Scholar
• Weiss GR, Margolin KA, Aronson FR et al. A randomized Phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. Oncol. 10, 275–281 (1992).
   PubMed Web of Science ®Google Scholar
• Koretz MJ, Lawson DH, York RM et al. Randomized study of interleukin-2 (IL-2) alone vs. IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch. Surg. 126, 898–903 (1991).
   PubMedGoogle Scholar
• Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85, 622–632 (1993).
   PubMed Web of Science ®Google Scholar
• Law TM, Motzer RJ, Mazumdar M et al. Phase III randomized trial of interleukin-2 with or without lymhokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824–832 (1995).
   PubMed Web of Science ®Google Scholar
• Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA. New directions in natural killer cell-based immunotherapy of human cancer. Expert Opin. Biol. Ther. 3, 237–250 (2003).
   PubMed Web of Science ®Google Scholar
• Osband ME, Lavin PT, Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335, 994–998 (1990).
   PubMed Web of Science ®Google Scholar
• Krane RJ, Carpiito GA, Ross SD et al. Treatment of metastatic renal cell carcinoma with autolymphocyte therapy. Low toxicity out-patient approach to adoptive immunotherapy without use of in vivo interleukin-2. Urology 35, 417–422 (1990).
   PubMedGoogle Scholar
• Mavligit GM. Immunologic effects of cimetidine: potential uses. Pharmacotherapy 7, S120–S124 (1987).
   Google Scholar
• Lavin PT, Maar R, Franklin M et al. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc. 24, 3059–3064 (1992).
   PubMedGoogle Scholar
• Cornforth AN, Schiltz PM, Nayak SK, Dillman RO. Characterization of autologous activated lymphocytes used for adoptive immunotherapy of renal cell and colon carcinoma. J. Immunother. 24, S4 (2001).
   Google Scholar
• Dillman RO, Soori G, DePriest C et al. Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a Phase II trial of the Cancer Biotherapy Research Group. Cancer Biother. Radiopharm. 18, 727–733 (2003).
   PubMedGoogle Scholar
• Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A Phase I trial of CD3/C28-activated T-cells (Xcellerated T-cells) and interleukin-2 in-patients with metastatic renal cell carcinoma. Clin. Cancer Res. 9, 3562–3570 (2003).
   PubMed Web of Science ®Google Scholar
• Curti BD, Ochoa AC, Urba WJ et al. Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of antiCD-3 stimulated T-cells: results from a Phase I trial in cancer patients. J. Immunother. 19, 296–308 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Speiss P, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Sharfman W, Murthy S et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastic renal cell carcinoma. Cancer Res. 51, 4199–4205 (1991).
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Hyatt C, McConnell S et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65, 413–421 (1996).
   PubMedGoogle Scholar
• Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J. Immunother. 20, 377–386 (1997).
   PubMed Web of Science ®Google Scholar
• Lewko WM, Hall PB, Oldham RK. Growth of tumor-derived activated T-cells for the treatment of advanced cancer. Cancer Biother. Radiopharm. 15, 357–366 (2000).
   PubMedGoogle Scholar
• Malone CC, Schiltz PM, Mackintosh AD et al. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother. Radiopharm. 16, 381–390 (2001).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Oldham RK, Barth NM et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma; a National Biotherapy Study Group trial. Cancer 68, 1–8 (1991).
   PubMed Web of Science ®Google Scholar
• Oldham RK, Dillman RO, Yannelli JR et al. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors; a National Biotherapy Study Group trial. Mol. Biother. 3, 68–73 (1991).
   PubMedGoogle Scholar
• Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin. Oncol. 22, 74–80 (1995).
   PubMed Web of Science ®Google Scholar
• Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, Phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17, 2521–2529 (1999).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Schiltz PM, DePriest C et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother. Radiopharm. 19, 730–737 (2004).
   PubMedGoogle Scholar
• Goedegebuure PS, Douville LM, Li H et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol. 8, 1939–1949 (1995).
   Google Scholar
• Belldegrun A, Pierce W, Kaboo R et al. Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J. Urol. 150, 1384–1390 (1993).
   PubMed Web of Science ®Google Scholar
• Chang AE, Li Q Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, antiCD-3 activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884–890 (2003).
   PubMed Web of Science ®Google Scholar
• Schleypen JS, Von Geldern M, Weiss EH et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int. J. Cancer 106, 905–912 (2003).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005).
   PubMed Web of Science ®Google Scholar
• Huang J, Khong HT, Dudley ME et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T-cells associated with tumor regression. J. Immunother. 28, 258–267 (2005).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Fluornoy N, Thomas ED et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Gommersall L, Hayne D, Lynch C, Joseph JV, Arya M, Patel HRH. Allogeneic stem-cell transplantation for renal-cell cancer. Lancet Oncol. 5, 561–567 (2004).
   PubMedGoogle Scholar
• Dorrschuck A, Schmidt A, Schnurer E et al. CD8+ cytotoxic T-lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 104, 2591–2599 (2004).
   PubMed Web of Science ®Google Scholar
• Strair RK, Schaar D, Medina D et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J. Clin. Oncol. 21, 3785–3791 (2003).
   PubMed Web of Science ®Google Scholar
• Igarashi T, Wynberg J, Srinivasan R et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104, 170–177 (2004).
   PubMed Web of Science ®Google Scholar
• Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99, 4234–4236 (2002).
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94, 2409–2415 (2002).
   PubMed Web of Science ®Google Scholar
• Childs RW, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750–758 (2000).
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Roigas J, Nagy M et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant. 34, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Ueno NT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102, 3829–3836 (2003).
   PubMed Web of Science ®Google Scholar
• Artz AS, Van Besien K, Zimmerman T et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 35, 253–260 (2005).
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Warren E, Thompson JA et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10, 7799–7811 (2004).
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kami M, Hori A et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp. Hematol. 32, 599–606 (2004).
   PubMed Web of Science ®Google Scholar
• Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103, 431–435 (2004).
   Google Scholar
• Rzepecki P, Zolnierek J, Sarosiek T, Langiewicz P, Szczylik C. Allogneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma-single center experience. Neoplasma 52, 238–242 (2000).
   Google Scholar
• Kessler DA, Siegel JP, Hoguchi PD, Zoon KC, Feiden KL, Woodcock J. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 329, 1169–1173 (1993).
   PubMed Web of Science ®Google Scholar